Shili Xu
Assistant Professor, Director of Crump Preclinical Imaging Technology Center
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
About
Shili Xu is an Assistant Professor and the Director of the Crump Preclinical Imaging Technology Center at UCLA, USA. His research focuses on advanced imaging techniques and cancer biology, with recent publications addressing topics such as three-dimensional printing of the human pericardium, gene therapy imaging, and the metabolic adaptations of cancer cells during therapy. He is actively involved in developing innovative methods for tracking tumor progression and characterizing cancer metabolism.
Articles (13)
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Background Resistance to existing therapies is a significant challenge in improving outcomes for glioblastoma (GBM) patients. Metabolic plasticity has emerged as an important contributor to therapy resistance, including radiation therapy (RT). Here, we investigated how GBM cells reprogram their glucose metabolism in response to RT to promote radiation resistance. Methods Effects of radiation on glucose metabolism of human GBM specimens were examined in vitro and in vivo with the use of metabolic and enzymatic assays, targeted metabolomics, and FDG-PET. Radiosensitization potential of interfering with M2 isoform of pyruvate kinase (PKM2) activity was tested via gliomasphere formation assays and in vivo human GBM models. Results Here, we show that RT induces increased glucose utilization by GBM cells, and this is accompanied with translocation of GLUT3 transporters to the cell membrane. Irradiated GBM cells route glucose carbons through the pentose phosphate pathway (PPP) to harness the antioxidant power of the PPP and support survival after radiation. This response is regulated in part by the PKM2. Activators of PKM2 can antagonize the radiation-induced rewiring of glucose metabolism and radiosensitize GBM cells in vitro and in vivo. Conclusions These findings open the possibility that interventions designed to target cancer-specific regulators of metabolic plasticity, such as PKM2, rather than specific metabolic pathways, have the potential to improve the radiotherapeutic outcomes in GBM patients.
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Collaborators (5)
Erina Vlashi
University of California
René Packard
University of California, Los Angeles
Evan Abt
Adjunct Assistant Professor
UCLA
Alex Wong
Assistant Professor
Yale University
Steve Cole
UCLA School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.